Blood levels of NfL are considered robust predictors of ALS progression [77], and their reduction, as shown in this case following BTT-based programmed fever, has been explored as a promising therapeutic target with disease-modifying potential, as exemplified by tofersen, an antisense oligonucleotide recently approved for the treatment of ALS in adults with SOD1 (superoxide dismutase-1) gene mutations [78]. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.